T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.07% |
| 2 | Healthcare | 18.73% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.39% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1851
Novavax
NVAX
$1.34B
| $830K | ﹤0.01% |
45,583
+2,473
| +6% | +$107K |
|
1852
BridgeBio Pharma
BBIO
$15.9B
| $828K | ﹤0.01% |
83,286
-6,911
| -8% | -$71.8K |
|
|
ARI
1853
Apollo Commercial Real Estate
ARI
$885M
| $825K | ﹤0.01% |
99,387
+3,881
| +4% | +$44.5K |
|
|
TEN
1854
DELISTED
Tenneco Inc. Class A Voting Common Stock
TEN
| $820K | ﹤0.01% |
47,144
-5,879
| -11% | -$110K |
|
1855
Theravance Biopharma
TBPH
$878M
| $818K | ﹤0.01% |
80,577
+9,264
| +13% | +$86.8K |
|
1856
Apogee Enterprises
APOG
$897M
| $815K | ﹤0.01% |
21,309
-9,160
| -30% | -$373K |
|
1857
Telephone and Data Systems
TDS
$4.03B
| $814K | ﹤0.01% |
58,497
+1,321
| +2% | +$21K |
|
|
BNR
1858
Burning Rock Biotech
BNR
$105M
| $811K | ﹤0.01% |
33,926
+971
| +3% | +$31.3K |
|
1859
Virtu Financial
VIRT
$5.05B
| $811K | ﹤0.01% |
39,043
+8,063
| +26% | +$185K |
|
|
AAWW
1860
DELISTED
Atlas Air Worldwide Holdings, Inc.
AAWW
| $810K | ﹤0.01% |
8,465
+1,893
| +29% | +$167K |
|
1861
Open Text
OTEX
$6.02B
| $804K | ﹤0.01% |
30,376
-9,809
| -24% | -$346K |
|
|
PENG
1862
Penguin Solutions Inc
PENG
$3.12B
| $804K | ﹤0.01% |
50,599
+3,101
| +7% | +$56.5K |
|
1863
Methode Electronics
MEI
$602M
| $799K | ﹤0.01% |
21,494
+4,183
| +24% | +$164K |
|
|
DEA
1864
Easterly Government Properties
DEA
$1.18B
| $797K | ﹤0.01% |
20,197
+4,008
| +25% | +$186K |
|
|
COWN
1865
DELISTED
Cowen Inc. Class A Common Stock
COWN
| $797K | ﹤0.01% |
20,612
-45,756
| -69% | -$1.66M |
|
1866
CVR Energy
CVI
$3.52B
| $795K | ﹤0.01% |
27,407
+3,673
| +15% | +$116K |
|
1867
Trupanion
TRUP
$1.33B
| $795K | ﹤0.01% |
13,367
+2,539
| +23% | +$170K |
|
1868
John Wiley & Sons Class A
WLY
$2.63B
| $793K | ﹤0.01% |
21,111
+2,802
| +15% | +$133K |
|
1869
Zillow
ZG
$8.15B
| $790K | ﹤0.01% |
27,577
-2,943
| -10% | -$103K |
|
1870
J&J Snack Foods
JJSF
$1.7B
| $789K | ﹤0.01% |
6,090
-116,433
| -95% | -$16.5M |
|
1871
Neogen
NEOG
$2.59B
| $789K | ﹤0.01% |
56,425
+16,262
| +40% | +$327K |
|
1872
Dana Inc
DAN
$3.26B
| $788K | ﹤0.01% |
68,937
+12,620
| +22% | +$191K |
|
1873
Horace Mann Educators
HMN
$2.09B
| $787K | ﹤0.01% |
22,286
+2,608
| +13% | +$93.9K |
|
1874
ImmunityBio
IBRX
$8.11B
| $785K | ﹤0.01% |
157,866
+11,149
| +8% | +$50.8K |
|
1875
Nu Skin
NUS
$236M
| $783K | ﹤0.01% |
23,447
+3,242
| +16% | +$135K |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.